FDA approves first drug-eluting contact lens The FDA has approved ACUVUE Theravision with Ketotifen (Johnson & Johnson Vision) as the first drug-eluting, vision-correcting contact lens. According to the company’s press release, each lens contains 19 mcg of ketotifen, which is an antihistamine. This contact lens will be indicated for the prevention of ocular itch due […]

Oculis and Accure Therapeutics have agreed to terms for Oculis to license ACT-01, which is under investigation for the prevention of damage to the optic nerve and retina, according to a press release. ACT-01, which will be renamed OCS-05, “is a first-in-class small molecule with neuroprotective activity that has shown positive results in animal models […]

Recently published findings from a phase 1 clinical trial (NCT03298672) of fosgonimeton (Athira Pharma) show that the treatment was safe and well tolerated in patients with Alzheimer disease (AD). These results add support to the development of the treatment, previously known as ATH-1017, as a novel therapeutic for people with AD and dementia.1,2 Investigators included […]